Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research

By David Holley, Xconomy San Antonio—A small Texas biotech that develops women’s health ...

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Ricardo Carrion, Jr., Ph.D. During the West African Ebola outbreak that began in 2013, an experimental ...

Texas Biomed files patent for novel HIV vaccine
November 19, 2012

By W. Scott Bailey, San Antonio Business Journal

The Texas Biomedical Research Institute (Texas Biomed) has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection.

The novel vaccine targets the outer layers of body structures that first come into contact with the virus.

The vaccine is designed so that it can be administered in a single dose and last the patient a lifetime. Texas Biomed officials say it could be adapted for use against other infections, as well.

"The development of an effective AIDS vaccine that restricts viral replication at the mucosal level of entry may be our best hope for controlling the HIV pandemic," says Marie-Claire Gauduin, Ph.D., who works in Texas Biomed's Department of Virology and Immunology and is a co-inventor on the patent with Philippe Blancou, Ph.D., a visiting scientist from the University of Nice-Sophia Antipolis in France.

"Only life-long stimulation of the immune system by the vaccine will be sufficient to achieve long-term protection," she adds.

One of the main reasons for the failure of HIV vaccines thus far is their inability to deliver antibody-producing cells for prolonged periods of time, thus only achieving weak and transient protection at best.

San Antonio-based Texas Biomed is one of the world's leading independent biomedical research institutions.


Stay informed. Subscribe to BioMed SA news alerts.